Norfolk, VA, May 10th, 2022 – ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, today announced the company secured regulatory approval from Germany’s Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) to conduct a Phase 1b inhaled lipopolysaccharide (LPS) challenge clinical trial in healthy volunteers to support development of the Company’s lead compound, RLS-0071, in severe asthma. RLS-0071 is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for hypoxic ischemic encephalopathy, severe asthma, and other rare diseases.
Read More